Back to search
FDAFDA · Food and drugs·Recall number Z-2803-2017

InflammaDry(R) AN RPS DIAGNOSTIC SOLUTION, Sample Collectors InflammaDry(R) is a rapid, immunoassay test for the visual, qualitative, in vitro detection of elevated levels of the MMP-9 protein in human tears, from patients suspected of having dry eye. InflammaDry is to be used to aid in the diagnosis of dry eye, in conjunction with other methods of clinical evaluation. This test is intended for prescription use at point-of-care sites.

Published August 9, 2017 · Recall initiated: June 22, 2017

Summary

FDA records medical device Class II recall Z-2803-2017, published August 9, 2017 and initiated June 22, 2017. Recalling firm: Quidel Corporation; Status: Terminated; Reported quantity: 1078 kits, 21,560 sample collectors; Lot: Lot numbers: 1705405, 1705359. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

In-house testing revealed the presence of plastic spurs at the tips of some Sample Collectors.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Quidel Corporation
Distributor
Nationwide Distribution including AR, AZ, CA, CO, CT, FL, GA, IL, IN, KY, LA, MA, MD, MI, MN, MO, NC, NE, NH, NJ, NY, OH, OK, PA, SC, SD, TX, VA, WA, & WV.
Lot
Lot numbers: 1705405, 1705359
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was InflammaDry(R) AN RPS DIAGNOSTIC SOLUTION, Sample Collectors InflammaDry(R) is a rapid, immunoassay test for the visual, qualitative, in vitro detection of elevated levels of the MMP-9 protein in human tears, from patients suspected of having dry eye. InflammaDry is to be used to aid in the diagnosis of dry eye, in conjunction with other methods of clinical evaluation. This test is intended for prescription use at point-of-care sites. recalled?

Yes. FDA published recall Z-2803-2017 on August 9, 2017. Reported hazard: In-house testing revealed the presence of plastic spurs at the tips of some Sample Collectors.

What should I do if I have this product?

Voluntary: Firm initiated · Letter